ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a San Diego-based biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, such as Parkinson’s disease psychosis, schizophrenia, and Rett syndrome, by targeting specific brain receptors. Its primary product, Nuplazid (pimavanserin), is the first FDA-approved treatment for hallucinations and delusions in Parkinson’s disease psychosis, approved in 2016, and remains its key revenue source, generating over $500 million in net sales in 2023. Founded in 1993, ACADIA continues to expand its pipeline with drugs like trofinetide (Daybue) for Rett syndrome, aiming to address unmet needs in neurology and psychiatry.